Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Silo Pharma (SILO) Non Operating Income (2019 - 2025)

Silo Pharma's Non Operating Income history spans 7 years, with the latest figure at $41028.0 for Q3 2025.

  • For Q3 2025, Non Operating Income fell 49.5% year-over-year to $41028.0; the TTM value through Sep 2025 reached $230702.0, down 32.59%, while the annual FY2024 figure was $312814.0, 39.33% up from the prior year.
  • Non Operating Income for Q3 2025 was $41028.0 at Silo Pharma, down from $44258.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $7.0 million in Q3 2021 and bottomed at -$279449.0 in Q4 2022.
  • The 5-year median for Non Operating Income is $48042.0 (2021), against an average of $380112.9.
  • The largest annual shift saw Non Operating Income plummeted 302.27% in 2022 before it surged 36154.42% in 2023.
  • A 5-year view of Non Operating Income shows it stood at -$114629.0 in 2021, then plummeted by 143.79% to -$279449.0 in 2022, then skyrocketed by 140.13% to $112148.0 in 2023, then dropped by 26.23% to $82732.0 in 2024, then plummeted by 50.41% to $41028.0 in 2025.
  • Per Business Quant, the three most recent readings for SILO's Non Operating Income are $41028.0 (Q3 2025), $44258.0 (Q2 2025), and $62684.0 (Q1 2025).